The poultry vaccines industry in Europe focuses on developing innovative solutions to protect poultry against various diseases that can impact growth and productivity. Companies in this sector are primarily biopharmaceutical firms, research institutions, and specialized startups that create vaccines tailored to prevent viral and bacterial ailments in birds, such as Newcastle disease and Avian influenza. As concerns about antibiotic resistance grow and animal welfare regulations strengthen, the industry is shifting towards more sustainable, health-centric vaccines. With ongoing advancements in biotechnology and genetic engineering, the future of poultry vaccines promises enhanced efficacy and safety, aligning with demands for sustainable agriculture.


This list features 11 prominent poultry vaccines investors based in Europe, ranging from venture capital firms to private equity entities. Operating from locales including Paris, Luxembourg, and London, these investors vary significantly in size—from nimble teams to larger firms with thousands of employees. Most were founded relatively recently, signaling increasing interest in the agri-tech sector, while their investments in 2024 reflect a robust focus on advancing animal health solutions. Notable players here have actively funded innovative companies such as Aviwell, Devenish Nutrition, and Animab, all contributing to the poultry vaccines space.


Top 11 Poultry Vaccines Investors in Europe


1. Bpifrance French Tech Accélération


Bpifrance French Tech Accélération is a venture capital firm based in Paris, Île-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding, export credit insurance, and private equity investments. The firm aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. In recent transactions, Bpifrance has been involved in funding companies like Aviwell, which focuses on vaccine development, and Osivax, which is working on vaccines for flu and coronaviruses. These investments highlight Bpifrance's active role in the biotechnology sector, particularly in vaccine innovation, making it a potential player in the poultry vaccines industry.


2. European Innovation Council (EIC)


The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, the EIC offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. In recent years, the EIC has been involved in several transactions relevant to the poultry vaccines industry, such as funding Ovagen, which raised over $8 million in a venture round and additional grant funding, and Aviwell, which received multiple grants totaling over $4 million. These investments highlight EIC's role in fostering innovation in the poultry sector, particularly in vaccine development and health solutions for poultry.


3. European Investment Bank (EIB)


The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. With a focus on promoting growth and job creation, EIB serves both public and private organizations seeking funding for innovative initiatives. Among its notable transactions, EIB has invested in Devenish Nutrition, an agri-technology company, providing €40 million to support research and development in animal nutrition and sustainability. Additionally, EIB's recent funding of €40 million to In Ovo, a Dutch company dedicated to stopping the culling of male chicks, highlights its commitment to advancing animal welfare in the poultry industry. These investments reflect EIB's strategic interest in enhancing the poultry sector, particularly in areas that intersect with health and innovation.


4. Seventure Partners

  • Website: seventure.fr
  • Type: Venture Capital
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1997
  • Headcount: 11-50
  • Number of deals in 2024: 21
  • LinkedIn: seventure-partners

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in managing funds for innovative companies in the digital technology and life sciences sectors. They focus on supporting startups and growth-stage companies through strategic funding. Notably, Seventure has participated in several transactions relevant to animal health, including ViroVet, which raised over 6 million euros to develop its veterinary product portfolio, and Proteon Pharmaceuticals, which aims to reduce antibiotic use in animal agriculture. These investments highlight Seventure's engagement in the animal health sector, which includes potential applications in poultry vaccines and overall livestock health.


5. Leaps by Bayer

  • Website: leaps.bayer.com
  • Type: Venture Capital
  • Headquarters: Berlin, Berlin, Germany
  • Founded year: 2015
  • Headcount: 11-50
  • Number of deals in 2024: 16
  • LinkedIn: leapsbybayer

Leaps by Bayer is a venture capital firm based in Berlin, Germany, founded in 2015. It specializes in biotechnology and agriculture, investing in early-stage companies that are pursuing scientific breakthroughs to tackle significant global challenges in health and food security. The firm actively incubates its portfolio companies, providing not just funding but also strategic support. Notable transactions include leading a $40 million Series B funding round for Ukko, a biotechnology startup, and participating in a $6 million Series B round for Amfora Inc. Additionally, they were involved in a $65 million Series C financing for AgBiome, a company focused on crop protection products. While these transactions do not directly relate to poultry vaccines, they indicate Leaps by Bayer's commitment to advancing agricultural technologies, which may include poultry health solutions in the future.


6. Boehringer Ingelheim Venture Fund

  • Website: boehringer-ingelheim-venture.com
  • Type: Venture Capital
  • Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund specializes in investing in pioneering science and biotechnology innovations, particularly within the healthcare sector. They provide both capital and expertise to startups, helping them develop and commercialize their products. Notably, the fund led a USD 14 million seed financing round for Delonix Bioworks, which is building synthetic biology vaccine platforms, indicating their interest in vaccine development. Additionally, they have participated in various funding rounds for companies like Amal Therapeutics and Topas Therapeutics, which are involved in innovative therapeutic solutions, further showcasing their commitment to advancing healthcare technologies.


7. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent private equity firm based in Stockholm, Sweden, founded in 1994. The firm specializes in a diverse range of investment strategies, including private equity, infrastructure, real estate, growth equity, and venture capital. EQT serves institutional investors by providing expertise in managing varied investment portfolios across multiple sectors and geographies. Notably, EQT has made significant investments in the veterinary services sector, acquiring companies like Evidensia Djursjukvård, the Nordic market leader in veterinary services, and IVC Evidensia, Europe's largest veterinary care provider. These transactions highlight EQT's commitment to the animal health industry, which is closely related to poultry health and vaccines, suggesting a strategic interest that could extend to poultry vaccines in the future.


8. IK Partners

  • Website: ikpartners.com
  • Type: Private Equity
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1989
  • Headcount: 201-500
  • Number of deals in 2024: 14
  • LinkedIn: ik-investment-partners

IK Partners is a private equity firm based in London, specializing in mid-market investments across Europe. Founded in 1989, the firm focuses on providing capital and strategic support to businesses in various sectors, including Business Services, Healthcare, Consumer, and Industrials. Notably, IK Partners has made several significant acquisitions in the animal health sector, including CEVA Santé Animale, which is a key player in the poultry vaccines market. Other relevant transactions include the acquisitions of CID LINES, Kersia, and Innovad, all of which contribute to the animal health and veterinary products landscape. By partnering with management teams in these companies, IK Partners aims to enhance growth and create long-term value, making them a relevant investor in the poultry vaccines industry.


9. The Yield Lab

  • Website: theyieldlab.com
  • Type: Venture Capital
  • Headquarters: Killiney, Dublin, Ireland
  • Founded year: 2014
  • Headcount: 11-50
  • Number of deals in 2024: 2
  • LinkedIn: theyieldlab

The Yield Lab is a venture capital firm based in Killiney, Dublin, Ireland, specializing in agrifood technology investments. Founded in 2014, the firm supports early-stage companies by providing venture capital funding, access to a global network of experts, and educational resources. The Yield Lab operates across multiple regions, focusing on helping entrepreneurs scale their innovations in the agrifood sector. Notably, they have invested in Aptimmune, which raised $6 million in a Series B round in January 2018, and $100,000 in a convertible note in August 2016. Aptimmune is known for developing vaccines for livestock, which aligns with the poultry vaccines industry. Additionally, they have invested in EIO Diagnostics and Botanical Solutions, further demonstrating their active role in agrifood technology, although these companies are not directly related to poultry vaccines.


10. Unigrains

  • Website: unigrains.fr
  • Type: Private Equity
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1963
  • Headcount: 51-200
  • Number of deals in 2024: 4
  • LinkedIn: unigrains

Unigrains is a private equity investment firm based in Paris, Île-De-France, France, founded in 1963. With over 60 years of experience, Unigrains specializes in the agro-food and agro-industry sectors, providing financial and strategic support to businesses to help them adapt to market changes. They have supported more than 1,000 companies and manage significant assets aimed at fostering growth and sustainability in agriculture and food production. Notably, Unigrains has been involved in several significant transactions, including a $70.9 million investment in Groupe Grimaud La Corbière, a company that plays a crucial role in poultry genetics, and a $563.9 million investment in Noriap, which operates in the agricultural sector. These transactions highlight Unigrains' commitment to the poultry industry and its potential interest in poultry vaccines.


11. V-Bio Ventures

  • Website: v-bio.ventures
  • Type: Venture Capital
  • Headquarters: Ghent, Flanders, Belgium
  • Founded year: 2015
  • Headcount: 1-10
  • Number of deals in 2024: 6
  • LinkedIn: v-bio-ventures

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in therapeutics, diagnostics, and sustainable agriculture. By providing capital and expertise, V-Bio Ventures aims to transform scientific innovations into impactful products that address unmet needs in healthcare and agriculture. Notably, V-Bio Ventures has participated in several significant transactions, including a seed investment in Animab, which is developing monoclonal antibodies for livestock health, and a substantial funding round for AstriVax, which is working on vaccine development. While their primary focus may not be exclusively on poultry vaccines, their involvement in livestock health and sustainable agriculture positions them as a relevant player in the broader context of animal health investments.



Poultry Vaccines Insights: Key Investors in Europe


InvestorHeadquarterSizeFoundedDeals 2024
Bpifrance French Tech AccélérationParis, Île-De-France, France1-102015198
European Innovation Council (EIC)Brussels, Brussels, Belgium201-500195857
European Investment Bank (EIB)Luxembourg1001-5000195899
Seventure PartnersParis, Île-De-France, France11-50199721
Leaps by BayerBerlin, Berlin, Germany11-50201516
Boehringer Ingelheim Venture FundIngelheim Am Rhein, Rhineland-Palatinate, Germany11-5020105
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
IK PartnersLondon, England, United Kingdom (UK)201-500198914
The Yield LabKilliney, Dublin, Ireland11-5020142
UnigrainsParis, Île-De-France, France51-20019634
V-Bio VenturesGhent, Flanders, Belgium1-1020156


Want to find more investors focusing on the poultry vaccines industry?

If you want to find more investors that are active in the poultry vaccinesindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!